• In the US pivotal phase III trial (n=80), Privigen delivered sustained effective protection from infections and favorable tolerability12
    • Annual rate* of serious bacterial infections (SBI) was 0.08, below FDA-required threshold of 1.0,13 and rate of other infections was 3.55
    • 97% of adverse reactions were non-serious
  • In patients (n=55) studied up to 41 months, Privigen continued to deliver favorable tolerability and showed lower rates of infection than the pivotal phase III trial14
    • Annual rate* of SBI was 0.02 and of other infections was 1.60
    • 93% of adverse reactions were mild or moderate

* Infections per subject year. Serious bacterial infections were defined as pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.

Annual rate of SBI with Privigen was 0.02 fin patients with PI
  • In the ITP clinical trial, 80.7% of subjects (46 of 57) responded to Privigen with a 150% rise in platelet count within 7 days10
  • Adverse events were generally mild or moderate10

Study was performed on 57 subjects with chronic ITP. Each subject had a platelet count of ≤20 x 109/L. Dose was 1 g/kg on 2 consecutive days. Primary endpoint was elevation of platelet count to at least 50 x 109/L within 7 days of infusion.

80.7% of patients with chronic ITP responded to Privigen

See Privigen dosing and infusion information

Use the guide or dosing calculator to determine the right amount of Privigen for your patients

Privigen is the first and only IVIg stabilized with proline

Find out what proline is and why it's in Privigen

You are now leaving the current website.

Do you want to continue?